Background: Antibiotic resistance is the main cause for Helicobacter pylori therapy
| INTRODUC TI ON
The current first-line triple therapy for Helicobacter pylori infection, recommended by the first Maastricht consensus report, 1 consisted of a proton-pump inhibitor (PPI), amoxicillin (AMX), and clarithromycin (CLR) or metronidazole (MTZ). Recent data 2, 3 show that the decrease of the efficacy of first-line triple therapy is mainly due to the increase of H. pylori resistance to CLR.
After an unsuccessful first-line regimen, guidelines propose an empirical levofloxacin triple therapy, non-bismuth quadruple therapy (sequential/concomitant/hybrid regimens), or bismuth-containing quadruple therapy (PPI plus bismuth plus any two of AMX/MTZ/ CLR/tetracycline-TET). 3, 4 When a second-line regimen fails, the empirical options are limited (longer treatment duration, higher acid inhibition, rifabutin triple therapy, or novel quadruple therapies). To solve this problem, antimicrobial susceptibility testing is one of the most promising ways, in order to avoid resistance and increase cure rates in high antibiotic resistance areas.
The treatment of many infectious diseases is guided by an antibiogram. Infection by H. pylori is often the exception. There is a false myth that H. pylori culture is troublesome and time-consuming 5 but it is a bacterium that grows in microaerobic atmosphere in 48-72 hours. The antimicrobial susceptibility data will be obtained in 7 days, and it is mandatory to re-plate the bacterium to grow it in quantity and spend 72 hours before reading of the MIC. Fortunately, H. pylori cause an infection that does not require an immediate treatment; moreover, on most occasions, the antibiogram is obtained long time before the patient returns to the consultation.
The objective of our study was to evaluate the effectiveness of susceptibility-guided triple therapies for 10 days in adults with resistant H. pylori isolates to CLR, to two antimicrobials (CLR, MTZ, or levofloxacin-LVX) and to three antibiotics (CLR, MTZ, and LVX). 
| MATERIAL S AND ME THODS

| Patients
| Susceptibility testing by E-test
Conclusions:
The implementation of susceptibility-guided triple therapy for 10 days leads to eradication rate ≥95% in naïve patients with H. pylori resistance to one or two families of antimicrobials. In naïve patients with H. pylori resistance to three families, OAR treatment achieved a 90% of eradication.
120 mg qid, TET 500 mg qid, and MTZ 500 tid). Patients with resis- Treatments were clearly explained to all patients. Drugs used in all groups were generic branding. Naïve patients were considered those not previously treated.
| Trial outcomes
Primary end point: Confirmation of H. pylori eradication by intention to treat (ITT) in each group was performed at least 6 weeks after treatment completion using the urea breath test (UBT) with 100 mg of urea (Otsuka Pharmaceutical Co, Ltd.: Tokio, Japan).
Secondary end point: adverse events associated with treatment.
Side effects were evaluated with a specific posttreatment questionnaire. Depending on the intensity, adverse effects were classified by physicians as mild (symptoms appear but do not interfere with daily life), moderate (symptoms interfere with daily life), or severe (symptoms present daily life or requires discontinuation of the drug). (Table 2 ). Naïve patients with single CLR resistance and with dual resistance achieved more than 95% of eradication rates, while these data for patients previously treated were 90%.
| RE SULTS
In naïve patients with triple-resistant H. pylori isolates to CLR, MTZ, and LVX, triple OAR-10-day therapy was more effective as first-line treatment than quadruple OABD-10 days (90% vs 50%, respectively; Table 3 ). The six patients who were not successfully eradicated with OAR-10-day therapy had susceptible H. pylori isolates to rifampin that shows a cross-resistance with rifabutin. On the other hand, the combination of a PPI plus AMX, DOX, and bismuth subcitrate-10 days seems to have a synergic effect and a good therapeutic outcome in patients who have failed two or three previous regimens (triple and/or non-bismuth quadruple therapies).
There were no differences in age, sex, or presentation of the disease among patients with successful eradication of those in whom the eradication of H. pylori failed (Table 4) . 
| D ISCUSS I ON
The results from this study showed that in Gipuzkoa, northern Spain, susceptibility-guided triple therapies for 10 days in naïve patients infected with single CLR-resistant and dual CLR-, MTZ-, or LVX-resistant isolates lead to eradication rate ≥95%.
In the Microbiology Department of HUD (San Sebastian), cultures are carried out "as routine practice" since 1994. 7 During the period 2000-2012, resistance to two or three antimicrobials was around 12.5% for dual resistance and 2.9% for triple resistance. In the context of a high CLR resistance, implementation of susceptibility-guided CLR-based triple therapy for 10 days has been previously proven to be effective, leading to a higher eradication success rate, lower cost, and fewer adverse events than empirical strategies in our clinical setting 9, 10 as well as in other countries.
12,13
Moreover, we also observed that susceptibility-guided triple therapies (a PPI plus any two of AMX/LEV/MTZ/CLR) for 10 days are (Table 3 ). Doxycycline without bismuth should not be prescribed.
There are few data on susceptibility-guided therapies for H pylori infection in areas with high rate of multiresistance to three antibiotics. Our results with the administration of rifabutin triple therapy for 10 days (OAR-10) are encouraging, especially when it was prescribed in naïve patients. The eradication rate was 90%
(nine of 10) in naïve patients and 37.5% (three of eight) in patients after previous H. pylori treatment failures. In some studies, 17,18 the majority of the rifabutin-resistant H. pylori isolates were isolated from patients after treatment failures, suggesting that previous unsuccessful attempts of eradication seem to be an important risk factor for the development of rifabutin resistance and/or antibiotic multiresistance.
A different option from rifabutin triple therapy is the combination of a PPI, AMX, DOX, and bismuth subcitrate quadruple therapy (OADB) for 10 days. Helicobacter pylori is well known to be hardly resistant to AMX and TET. The addition of bismuth subcitrate increases eradication when is included in quadruple therapies.
Inclusion of antisecretory drugs (PPIs) in H. pylori eradication is crucial to optimize the local activity of antibiotics via synergism. In our experience, the OADB-10-day regimen eradicated five of seven (71.3%) patients infected with triple CLR-, MTZ-, and LVX-resistant H. pylori isolates.
In our series, no patient developed severe adverse events. A possible explanation may be the short duration of treatments. Unfortunately, in European treatment-naïve patients, the mean rate of resistance to clarithromycin is 22% and dual resistance to clarithromycin and metronidazole 13%. 19 These data discourage the empirical use of standard triple therapy and quadruple therapies with CLR/MTZ. Acquisition of antibiotic resistance increases after each failed eradication attempt. In our opinion, the clinical practice of pre-treatment H. pylori antibiotic sensitivity test contributes to the high eradication rate in all patients (naïve or after the failure to treatment).
In conclusion, CLR resistance as well as multiresistance to various families of antibiotics was a frequent event in northern Spain and its detection is a priority as it constitutes the main cause of H. pylori treatment failure. In this context, the implementation of susceptibility-guided triple therapies for 10 days is cost-effective and leads to an eradication rate ≥94% in patients infected with single CLR-resistant and with double-resistant H. pylori isolates (CLR, MTZ, or LVX). In naïve patients infected with triple-resistant H. pylori isolates to CLR, MTZ, and LVX, the best regimen was OAR for 10 days eradicating the bacteria in 90% of the patients.
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